🎈 Up Big Today: Find today's biggest gainers (some over 50%!) with our free screenerTry Stock Screener

IFRC says shortage of testing, vaccines hampers mpox response in Africa

Published 08/16/2024, 06:14 AM
Updated 08/16/2024, 07:01 AM
© Reuters. Christian Musema, a laboratory nurse, verifies samples taken from a child declared a suspected case of monkeypox virus that sparks off a painful rash, enlarged lymph nodes and fever; and recovered, collects water at the the treatment centre in Munigi, fol

By Ludwig Burger and Miranda Murray

(Reuters) -Far more diagnostic kits, treatments and vaccines need to be shipped to Africa to respond adequately to the outbreak of a new strain of the mpox virus there, an official of the Red Cross and Red Crescent humanitarian network said on Friday.

"There is a critical shortage of testing, treatment and vaccines across the continent," Bronwyn Nichol of the International Federation of Red Cross and Red Crescent Societies (IFRC) said in a media call on Friday.

"These shortages are severely hampering the ability to contain the outbreak."

Health officials on Thursday confirmed an infection with the new mpox strain in Sweden, the first sign of its spread outside Africa after the World Health Organization declared the disease a global public health emergency.

IFRC's Nichol expressed concern that cases outside of Africa could prompt developed countries to go back on existing commitments to support the response of international groups in Africa.

"I’m sure this will make some governments think a bit more as well... hopefully that doesn’t change some of the planned donations," she said.

Speaking on the same media call on Friday, WHO official Margaret Harris said she expects more cases outside Africa to emerge soon, also as a result of heightened monitoring.

© Reuters. Christian Musema, a laboratory nurse, verifies samples taken from a child declared a suspected case of monkeypox virus that sparks off a painful rash, enlarged lymph nodes and fever; and recovered, collects water at the the treatment centre in Munigi, following Mpox cases in Nyiragongo territory near Goma, North Kivu province, Democratic Republic of the Congo July 19, 2024. REUTERS/Arlette Bashizi

The case in Sweden "shows the system is working and that countries have stepped up their vigilance, what to look for. We expect that we will see cases elsewhere," said Harris.

The head of global vaccine group Gavi told Reuters on Friday it has up to $500 million to spend on getting shots to countries affected by the escalating mpox outbreak in Africa.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.